In response to the American Society of Clinical Oncology’s (ASCO) latest policy statement on the impact of utilization management for cancer drug therapies, Oncology Analytics, Inc. www.oncologyanalytics.com, a comprehensive oncology benefits management company serving health plans, providers, and patients in the U.S. market and Puerto Rico, today announces that its cancer benefit management programs are aligned with the recommendations provided by ASCO to support and promote patient access to high-value, high-quality cancer care.

Oncology Analytics’ proprietary MATIS™ utilization management software is comprised of over 5,000 protocols for medical oncology, radiation therapy and molecular and genetic testing. Treatments that provide high quality and high value evidence based care are automatically processed by MATIS™.  In OA’s experience, over 65% of requests meet these parameters, providing physicians with instantaneous approval of their requests.

Another 25% of the time, OA requires additional information on the patient before rendering an approval for treatment. “Requests for information are completed within 24 hours, and often far less” confirms Dr. Marc Fishman, CEO of Oncology Analytics. “The balance of cases require consultation between our oncologists and the prescribing oncologist to discuss the most effective and least toxic therapy. Utilizing OA’s deep clinical resources, including our full time medical directors and board certified oncology pharmacists, supported, as needed, by our Distinguished Academic Advisory Board, OA can review the most complex cases, usually within hours of the request. OA’s clinical resources function as a virtual tumor board, providing treating physicians with a comprehensive assessment of their most complex cases,” states Dr. Fishman.

OA’s MATIS™ utilization management program is founded on a careful review of the scientific literature and evidence-based guidelines. “We do not use step-therapy, specialty specific tiers, or restrictive formularies,” says Dr. Fishman, “and we work with health plans to provide custom fee schedules to assure appropriate compensation for oncology pharmaceuticals, diminishing incentives to utilize more costly pharmaceuticals”.

The advantages of MATIS™ include improving efficiencies in processing times to deliver timely and accurate responses to provider requests and providing information on value-based, evidence-based treatment alternatives consistent with the highest standards of oncology care.   MATIS™ gives providers choices for their patients, which allows providers to deliver the best oncology treatments with greater confidence and at lower costs to patients and health plans.  Additionally, MATIS™ enables providers to automatically confirm eligibility information at the time of authorization, populating all relevant fields with the most current information.  Due to these benefits, Oncology Analytics has national provider satisfaction scores in the 96% range.

“The mission of Oncology Analytics is to assure that patients receive high quality, cost effective cancer care while minimizing administrative burdens for providers,” says Dr. Fishman. “Our primary concern has been, and will always be the patient.”